[HTML][HTML] Generation and testing of clinical-grade exosomes for pancreatic cancer

M Mendt, S Kamerkar, H Sugimoto, KM McAndrews… - JCI insight, 2018 - ncbi.nlm.nih.gov
M Mendt, S Kamerkar, H Sugimoto, KM McAndrews, CC Wu, M Gagea, S Yang, EVR Blanko…
JCI insight, 2018ncbi.nlm.nih.gov
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to
efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells.
Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes
employing good manufacturing practice (GMP) standards. A standard operating procedure
was established to generate engineered exosomes with the ability to target oncogenic Kras
(iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo …
Abstract
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.
ncbi.nlm.nih.gov